Biotique Systems, Inc. - News & Press

05

SANTA CLARA, Calif. and EMERYVILLE, Calif., September 05, 2002 — Affymetrix, Inc. (NASDAQ: AFFX) and Biotique Systems, Inc. today announced that data from the Affymetrix/ National Cancer Institute human transcriptome initiative is now freely available to the public via the Web through a version of Biotique’s data integration and analysis software platform.

The initial online offering consists of transcript data for chromosomes 21 and 22, and is available at www.affymetrix.com/transcriptome/index.affx and www.biotiquesystems.com. These data were originally published in the May 3, 2002 issue of Science, and suggest that large regions of the human genome beyond the coding segments appear to be transcribed. Biotique’s analysis software allows scientists to view public gene annotations and probes collated with novel gene transcript predictions derived from this dataset.

"Through this public resource, scientists can now easily access and identify novel transcribed regions as well as alternative splice variants to better understand the structure and complexity of the genome," said Thomas Gingeras, Ph.D., Vice President of Biological Research at Affymetrix, and senior author of the Science article. "By making these results publicly and freely available, we hope to encourage further advances in evaluating the transcriptome and its role in human health.”

“We are delighted that Affymetrix has chosen the Biotique Local Integration System (BLIS) to house its transcriptome data and to provide an interface for researchers to access, query and use this information,” said John Burke, President and Chief Scientific Officer, Biotique Systems.

The transcriptome is defined as the complete collection of transcribed elements of the genome. In addition to mRNAs, it also represents non-coding RNAs that are used for structural and regulatory purposes. Alterations in the structure or levels of expression of any one of these RNAs or their proteins could contribute to disease. An understanding of the transcriptome may provide valuable insights in the research for novel drugs.

About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the genomic revolution. By applying the principles of semiconductor technology to the life sciences, Affymetrix develops and commercializes systems that help scientists improve the quality of life. The Company's customers include pharmaceutical, biotechnology, agrochemical, diagnostics and consumer products companies as well as academic, government and other non- profit research institutes. Affymetrix offers an expanding portfolio of integrated products and services, including its integrated GeneChipâ platform, to address growing markets focused on understanding the relationship between genes and human health. Additional information on Affymetrix can be found at www.affymetrix.com

About Biotique Systems:
Biotique Systems, Inc. was founded in 2001 to solve critical issues in the life sciences. The Company provides decision support tools and services for the emerging field of pharmacogenomics. Biotique’s pharmaceutical and biotechnology customers have adopted the Company’s solutions to integrate their proprietary, third-party and public data sources, optimize biochip designs and other assays, and perform comparative genomic analysis. As a result, Biotique is enabling the next generation of genomic discovery. For more information, contact Biotique Systems, Inc. at 510-595-3110 or e-mail inquire@biotiquesystems.com or visit www.biotiquesystems.com.

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to risks of the Company’s ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, personnel retention, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2001 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Note: Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.

Actions:E-mail | Permalink |